PET/Computed Tomography in Renal, Bladder, and Testicular Cancer

Overview

Journal PET Clin

Specialty Radiology

Date 2015 Jun 24

PMID 26099672

Citations 8

Authors

Kirsten Bouchelouche

Peter L Choyke

Affiliations

Soon will be listed here.

Abstract

Imaging plays an important role in the clinical management of cancer patients. Hybrid imaging with PET/computed tomography (CT) is having a broad impact in oncology, and in recent years PET/CT is beginning to have an impact in urooncology. In both bladder and renal cancers, there is a need to study the efficacy of other tracers than F-18 fluorodeoxyglucose (FDG), particularly tracers with limited renal excretion. Thus, new tracers are being introduced. This review focuses on the clinical role of FDG and other PET agents in renal, bladder, and testicular cancers.

Citing Articles

The role of F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!.

Hung T, McLean L, Mitchell C, Pascoe C, Lawrentschuk N, Murphy D Cancer Imaging. 2019; 19(1):28.

PMID: 31142361 PMC: 6542013. DOI: 10.1186/s40644-019-0217-5.

F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis-A Multicenter Retrospective Study.

Zattoni F, Incerti E, Dal Moro F, Moschini M, Castellucci P, Panareo S Cancers (Basel). 2019; 11(5).

PMID: 31137599 PMC: 6562413. DOI: 10.3390/cancers11050700.

Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.

Joice G, Rowe S, Gorin M, Pierorazio P Curr Urol Rep. 2018; 19(12):110.

PMID: 30413968 DOI: 10.1007/s11934-018-0863-3.

Carbon-11 and Fluorine-18 Labeled Amino Acid Tracers for Positron Emission Tomography Imaging of Tumors.

Sun A, Liu X, Tang G Front Chem. 2018; 5:124.

PMID: 29379780 PMC: 5775220. DOI: 10.3389/fchem.2017.00124.

Current Concepts in the Management of Muscle Invasive Bladder Cancer.

Krishna S, Konety B Indian J Surg Oncol. 2017; 8(1):74-81.

PMID: 28127187 PMC: 5236024. DOI: 10.1007/s13193-016-0586-1.

References

De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K . Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol. 2001; 19(17):3740-4. DOI: 10.1200/JCO.2001.19.17.3740. View

Czarnecka A, Kornakiewicz A, Kukwa W, Szczylik C . Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. Future Oncol. 2014; 10(6):1095-111. DOI: 10.2217/fon.13.258. View

Johnson J, Mattrey R, Phillipson J . Differentiation of seminomatous from nonseminomatous testicular tumors with MR imaging. AJR Am J Roentgenol. 1990; 154(3):539-43. DOI: 10.2214/ajr.154.3.2106218. View

Sahni V, Silverman S . Imaging management of incidentally detected small renal masses. Semin Intervent Radiol. 2014; 31(1):9-19. PMC: 3930647. DOI: 10.1055/s-0033-1363838. View

Letocha H, Ahlstrom H, Malmstrom P, Westlin J, Fasth K, Nilsson S . Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Urol. 1994; 74(6):767-74. DOI: 10.1111/j.1464-410x.1994.tb07123.x. View

Jana S, Blaufox M . Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med. 2005; 36(1):51-72. DOI: 10.1053/j.semnuclmed.2005.09.001. View

Siekiera J, Malkowski B, Jozwicki W, Jasinski M, Wronczewski A, Pietrzak T . Can we rely on PET in the follow-up of advanced seminoma patients?. Urol Int. 2012; 88(4):405-9. DOI: 10.1159/000337056. View

Maurer T, Souvatzoglou M, Kubler H, Opercan K, Schmidt S, Herrmann K . Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol. 2011; 61(5):1031-8. DOI: 10.1016/j.eururo.2011.12.009. View

Wang N, Jiang P, Lu Y . Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for detecting bladder lesions? A meta-analysis of the literature. Urol Int. 2013; 92(2):143-9. DOI: 10.1159/000351964. View

10.

Makis W, Ciarallo A, Rakheja R, Probst S, Hickeson M, Rush C . Spectrum of malignant renal and urinary bladder tumors on 18F-FDG PET/CT: a pictorial essay. Clin Imaging. 2012; 36(6):660-73. DOI: 10.1016/j.clinimag.2012.01.010. View

11.

Drieskens O, Oyen R, van Poppel H, Vankan Y, Flamen P, Mortelmans L . FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005; 32(12):1412-7. DOI: 10.1007/s00259-005-1886-9. View

12.

Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K . FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 2009; 57(4):641-7. DOI: 10.1016/j.eururo.2009.05.014. View

13.

Yildirim-Poyraz N, Ozdemir E, Uzun B, Turkolmez S . Dual phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer. Rev Esp Med Nucl Imagen Mol. 2012; 32(4):214-21. DOI: 10.1016/j.remn.2012.10.004. View

14.

Ravina M, Hess S, Chauhan M, Jacob M, Alavi A . Tumor thrombus: ancillary findings on FDG PET/CT in an oncologic population. Clin Nucl Med. 2014; 39(9):767-71. DOI: 10.1097/RLU.0000000000000451. View

15.

de Jong I, Pruim J, Elsinga P, Jongen M, Mensink H, Vaalburg W . Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging. 2002; 29(10):1283-8. DOI: 10.1007/s00259-002-0881-7. View

16.

Witjes J, Comperat E, Cowan N, De Santis M, Gakis G, Lebret T . EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2013; 65(4):778-92. DOI: 10.1016/j.eururo.2013.11.046. View

17.

Apolo A, Riches J, Schoder H, Akin O, Trout A, Milowsky M . Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010; 28(25):3973-8. PMC: 2940395. DOI: 10.1200/JCO.2010.28.7052. View

18.

Divgi C, Uzzo R, Gatsonis C, Bartz R, Treutner S, Yu J . Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2012; 31(2):187-94. PMC: 5795663. DOI: 10.1200/JCO.2011.41.2445. View

19.

Cremerius U, Wildberger J, Borchers H, Zimny M, Jakse G, Gunther R . Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. Urology. 1999; 54(5):900-4. DOI: 10.1016/s0090-4295(99)00272-1. View

20.

Kaufman D, Shipley W, Feldman A . Bladder cancer. Lancet. 2009; 374(9685):239-49. DOI: 10.1016/S0140-6736(09)60491-8. View